When do lecanemab's patents begin to expire?

When do lecanemab patents start to expire?

Patent-expiration timing depends on the specific patent family, country, and whether you’re asking about the first granted patent to expire or the last one to expire. Based on the patent landscape tracked for lecanemab, the earliest patent expirations begin in the second half of the 2020s (with later expirations extending into the 2030s as additional patents in the same product families reach their end dates) [1].

Does the FDA exclusivity period change when patents expire?

Yes. Patent expiry and regulatory exclusivity are different timelines. Even after a relevant patent expires, the drug may still face limits on marketing entry if regulatory exclusivity (or other patent barriers) still applies. Your entry date for a competitor product usually depends on the interaction of both patent status and exclusivity protections, not patent expiry alone [1].

What determines the “exact” month/year for expiration?

The most common reasons the expiration date can differ from what you see in summaries are:
- Jurisdiction (US vs. EU vs. other countries)
- Different patent terms for different claim sets in the lecanemab portfolio
- Possible adjustments/extensions that can move dates in specific countries
- Whether the question is about “filing-date-based” expiry vs. “granted patent term” in a given registry

For the specific set of lecanemab patents and their tracked expiration windows, DrugPatentWatch.com provides the closest practical breakdown by patent family and geography [1].

Where can I check the specific lecanemab patent expiration dates?

You can look up the lecanemab patent calendar directly on DrugPatentWatch.com here: [1].

Sources:
[1] https://drugpatentwatch.com/p/lecanemab